The Clinical Trials Program at Wentworth-Douglass Hospital offers our cancer patients participation in studies supported by the National Cancer Institute's Cancer Trial Support Unit (CTSU) as well as those conducted by the private sector through biopharmaceutical companies. The clinical trials currently available include:
| | |
Breast | NSABP B42 | A Phase III, Letrozole versus Placebo in Postmenopausal Women with Breast Cancer who have completed at least 5 yrs of Adjuvant Aronatase Inhibitor (Al).
|
Breast | SWOG S0221 | A Phase III, Cyclophosphamide and Doxirubicin
versus Paclitaxel in with High Risk Node negative Breast Cancer
|
Breast | SWOG S0307 | A Phase lll, Bisphosphonates as Adjunct Therapy for Primary Breast Cancer
|
Breast | NSABP B39 | A Phase lll, Conventional Whole Breast Irradiation(WBI) Versus PartiaL Breast Iradiation(PBI) for Women with High Risk Breast Cancer
|
Breast | NSABP B40 | A Phase lll, Evaluating effect on Pathologic Complete Response (pCR) of adding Capecitabine or Gemcitabine to Docetaxel when administered before AC with or without Bevacizumab and correlative science studies attempting to identify predictors of high likelihood for pCR with each regimen in women with breast cancer.
|
 |
Please contact our Clinical Research Coordinator at 603-740-2150 to find out more about these studies.
In addition, the information below is presented to help you learn more about clinical research.
Websites of Interest:
www.ciscrp.org
www.clinicaltrials.gov National Institutes of Health
|
